These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 31097447)
21. Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model. Shimozono R; Asaoka Y; Yoshizawa Y; Aoki T; Noda H; Yamada M; Kaino M; Mochizuki H Mol Pharmacol; 2013 Jul; 84(1):62-70. PubMed ID: 23592516 [TBL] [Abstract][Full Text] [Related]
22. The role of oxidative stress in NASH and fatty liver model. Sakaida I; Okita K Hepatol Res; 2005 Oct; 33(2):128-31. PubMed ID: 16214393 [TBL] [Abstract][Full Text] [Related]
23. Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic Steatohepatitis. Tølbøl KS; Stierstorfer B; Rippmann JF; Veidal SS; Rigbolt KTG; Schönberger T; Gillum MP; Hansen HH; Vrang N; Jelsing J; Feigh M; Broermann A Dig Dis Sci; 2019 May; 64(5):1238-1256. PubMed ID: 30511198 [TBL] [Abstract][Full Text] [Related]
24. Dietary Iron Supplementation Alters Hepatic Inflammation in a Rat Model of Nonalcoholic Steatohepatitis. Atarashi M; Izawa T; Miyagi R; Ohji S; Hashimoto A; Kuwamura M; Yamate J Nutrients; 2018 Feb; 10(2):. PubMed ID: 29401710 [TBL] [Abstract][Full Text] [Related]
25. Increased expression of cyclooxygenase-2 protein during rat hepatocarcinogenesis caused by a choline-deficient, L-amino acid-defined diet and chemopreventive efficacy of a specific inhibitor, nimesulide. Denda A; Kitayama W; Murata A; Kishida H; Sasaki Y; Kusuoka O; Tsujiuchi T; Tsutsumi M; Nakae D; Takagi H; Konishi Y Carcinogenesis; 2002 Feb; 23(2):245-56. PubMed ID: 11872629 [TBL] [Abstract][Full Text] [Related]
26. Antihypertensive therapy improves insulin resistance and serum levels of interleukin-6 and -10 in spontaneously hypertensive rats with steatohepatitis. Kozono M; Uto H; Ibusuki R; Arima S; Oda K; Taguchi H; Sasaki F; Nasu Y; Hashimoto S; Setoyama H; Kanmura S; Numata M; Tsubouchi H; Ido A Mol Med Rep; 2016 Dec; 14(6):5385-5394. PubMed ID: 27779710 [TBL] [Abstract][Full Text] [Related]
27. Pitavastatin inhibits hepatic steatosis and fibrosis in non-alcoholic steatohepatitis model rats. Miyaki T; Nojiri S; Shinkai N; Kusakabe A; Matsuura K; Iio E; Takahashi S; Yan G; Ikeda K; Joh T Hepatol Res; 2011 Apr; 41(4):375-85. PubMed ID: 21276150 [TBL] [Abstract][Full Text] [Related]
29. Selective autophagy associated with iron overload aggravates non-alcoholic steatohepatitis via ferroptosis. Honma K; Kirihara S; Nakayama H; Fukuoka T; Ohara T; Kitamori K; Sato I; Hirohata S; Fujii M; Yamamoto S; Ran S; Watanabe S Exp Biol Med (Maywood); 2023 Jul; 248(13):1112-1123. PubMed ID: 37646078 [TBL] [Abstract][Full Text] [Related]
30. Trans-portal hepatic infusion of cultured bone marrow-derived mesenchymal stem cells in a steatohepatitis murine model. Sasaki R; Takami T; Fujisawa K; Matsumoto T; Ishikawa T; Yamamoto N; Sakaida I J Clin Biochem Nutr; 2020 Nov; 67(3):274-282. PubMed ID: 33293768 [TBL] [Abstract][Full Text] [Related]
31. Non-alcoholic steatohepatitis-associated hepatic fibrosis and hepatocellular carcinoma in a combined mouse model of genetic modification and dietary challenge. Amano Y; Shimizu F; Yasuno H; Harada A; Tsuchiya S; Isono O; Nagabukuro H; Tozawa R Hepatol Res; 2017 Jan; 47(1):103-115. PubMed ID: 26992446 [TBL] [Abstract][Full Text] [Related]
32. Combining probiotics and an angiotensin-II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis. Sawada Y; Kawaratani H; Kubo T; Fujinaga Y; Furukawa M; Saikawa S; Sato S; Seki K; Takaya H; Okura Y; Kaji K; Shimozato N; Mashitani T; Kitade M; Moriya K; Namisaki T; Akahane T; Mitoro A; Yamao J; Yoshiji H Hepatol Res; 2019 Mar; 49(3):284-295. PubMed ID: 30365236 [TBL] [Abstract][Full Text] [Related]
33. Enhancing hepatic fibrosis in spontaneously hypertensive rats fed a choline-deficient diet: a follow-up report on long-term effects of oxidative stress in non-alcoholic fatty liver disease. Yamamoto H; Kanno K; Ikuta T; Arihiro K; Sugiyama A; Kishikawa N; Tazuma S J Hepatobiliary Pancreat Sci; 2016 May; 23(5):260-9. PubMed ID: 26880573 [TBL] [Abstract][Full Text] [Related]
34. Elevated free cholesterol in a p62 overexpression model of non-alcoholic steatohepatitis. Simon Y; Kessler SM; Gemperlein K; Bohle RM; Müller R; Haybaeck J; Kiemer AK World J Gastroenterol; 2014 Dec; 20(47):17839-50. PubMed ID: 25548482 [TBL] [Abstract][Full Text] [Related]
35. [The role of iron overload in the progression of nonalcoholic steatohepatitis (NASH)]. Atarashi M; Izawa T; Kuwamura M; Yamate J Nihon Yakurigaku Zasshi; 2019; 154(2):61-65. PubMed ID: 31406044 [TBL] [Abstract][Full Text] [Related]
36. Altered Gut Microbiota Composition and Immune Response in Experimental Steatohepatitis Mouse Models. Ishioka M; Miura K; Minami S; Shimura Y; Ohnishi H Dig Dis Sci; 2017 Feb; 62(2):396-406. PubMed ID: 27913996 [TBL] [Abstract][Full Text] [Related]